Bronchiolitis fibrosa obliterans (also called bronchiolitis obliterans / obliterative or constrictive bronchiolitis) is a chronic lung disease that scars and narrows the smallest breathing tubes in the lungs, called bronchioles. Over time, the inner lining of these tiny tubes gets injured (by infection, toxic fumes, immune reactions, or after a transplant). The body tries to heal the injury, but instead it lays down fibrous scar tissue that tightens the airway like a shrinking ring. Because those airway rings become stiff and narrow, air cannot flow out easily, especially when you breathe out. This causes long-lasting shortness of breath, cough, wheeze, and exercise intolerance. The problem is mostly irreversible because scarred tissue does not return to normal. Doctors often call this condition constrictive bronchiolitis or obliterative bronchiolitis, and when it follows a lung or bone-marrow transplant it is tracked as bronchiolitis obliterans syndrome (BOS) or part of chronic lung allograft dysfunction (CLAD). The pattern on lung tests is usually airflow obstruction that does not fully improve with inhalers. High-resolution CT scans often show air-trapping and “mosaic” attenuation (patchy areas of darker and lighter lung) due to uneven ventilation in different parts of the lung. radiopaedia.org+4NCBI+4PMC+4
Bronchiolitis fibrosa obliterans is a disease of the small airways (bronchioles). After an injury (for example, toxic fumes, infection, or immune reactions after a transplant), the bronchioles become inflamed and then scarred and narrowed. Over time, the scarring can “obliterate” the airway lumen so air cannot flow out easily. This creates fixed airflow obstruction that usually does not respond well to typical asthma medicines. When this condition appears after a lung transplant (or sometimes after bone-marrow/hematopoietic stem-cell transplant), it’s often called bronchiolitis obliterans syndrome (BOS). The disease is chronic, often progressive, and can cause cough, wheeze, and breathlessness on exertion, sometimes needing oxygen or even lung transplantation in severe, refractory cases. NCBI+2publications.ersnet.org+2
Other names
Constrictive bronchiolitis
Obliterative bronchiolitis
Bronchiolitis obliterans
Bronchiolitis obliterans syndrome (BOS) (after transplant; a surveillance term based on spirometry decline)
Popcorn-worker’s lung / flavorings-related lung disease (workplace exposure to diacetyl in some food/flavoring settings) NCBI+2publications.ersnet.org+2
Types
Post-infectious bronchiolitis obliterans (PIBO/PIOB)
Follows a significant lower-respiratory infection (classically adenovirus; also reported with RSV, measles, Mycoplasma, Bordetella). Scar forms after epithelial injury. Seen in children and adults. Karger Publishers+2PMC+2Transplant-related (BOS / CLAD-BO phenotype)
After lung transplant or hematopoietic stem-cell transplant, immune injury to small airways leads to a sustained fall in FEV₁ (a key spirometry measure). Diagnosis and staging use ISHLT criteria. publications.ersnet.org+2PMC+2Inhalational/toxic exposure–related
Linked to diacetyl and related flavoring chemicals (coffee roasting, popcorn manufacturing), burn-pit smoke, chlorine and other irritant gases, and battlefield exposures. nejm.org+4CDC+4CDC+4Autoimmune/connective-tissue disease–associated
Most often rheumatoid arthritis, but also Sjögren’s, lupus, and systemic sclerosis; IBD is also reported. atsjournals.org+2publications.ersnet.org+2Drug- or radiation-associated / hypersensitivity contexts
Less common; reported with certain medications, chronic hypersensitivity pneumonitis, and after thoracic radiation (evidence is largely case-series/observational). pneumon.orgCryptogenic (no clear trigger)
When careful evaluation finds no cause, some patients are labeled cryptogenic constrictive bronchiolitis. PMC
Causes
Adenovirus lower-respiratory infection – damages bronchiolar lining; scarring narrows the lumen and causes fixed obstruction after the acute illness resolves. Karger Publishers
Respiratory syncytial virus (RSV) – severe bronchiolitis can lead to later airway fibrosis in susceptible patients. Karger Publishers
Measles – classic infections linked to PIBO, especially where vaccination rates are low. Karger Publishers
Mycoplasma pneumoniae – can injure bronchiolar epithelium and trigger scarring in small airways. Lippincott Journals
Bordetella pertussis (whooping cough) – post-infectious airway remodeling may persist as small-airway obstruction. Karger Publishers
Severe bacterial pneumonia – intense inflammation may heal with concentric fibrosis around bronchioles. (General framework from bronchiolitis reviews.) Karger Publishers
Lung transplantation (BOS/CLAD) – chronic immune injury to the graft’s small airways causes progressive, fixed obstruction tracked by FEV₁ decline. publications.ersnet.org
Hematopoietic stem-cell transplantation (GVHD-related airway disease) – immune-mediated injury produces BO pattern with persistent airflow obstruction. PMC
Flavoring chemicals (diacetyl; 2,3-pentanedione) – occupational exposure can cause disabling BO; removal from exposure prevents further harm but does not reverse scarring. CDC+1
Coffee roasting/flavoring environments – natural or added diacetyl exposures have been implicated in BO clusters. deohs.washington.edu
Burn-pit and deployment-related exposures – soldiers with dyspnea after Iraq/Afghanistan deployments had biopsy-proven constrictive bronchiolitis. nejm.org+1
Chlorine or other irritant gas inhalation – acute chemical injury can lead to chronic small-airway fibrosis. nejm.org
Rheumatoid arthritis – the most frequent connective-tissue association; often in middle-aged women with long-standing RA. publications.ersnet.org+1
Sjögren disease – autoimmune airway inflammation may progress to constrictive bronchiolitis. publications.ersnet.org
Systemic lupus erythematosus/systemic sclerosis – less common but reported associations with small-airway fibrotic disease. Karger Publishers
Inflammatory bowel disease (ulcerative colitis/Crohn’s) – extra-intestinal airway disease can include constrictive bronchiolitis. PMC+1
Chronic hypersensitivity pneumonitis – ongoing antigen exposure can damage small airways and cause fixed airflow limitation. (Review data.) pneumon.org
Certain drugs / therapies – scattered case series describe BO after select medications or thoracic radiation; mechanism is toxic/immune injury to bronchioles. pneumon.org
Post-viral bronchiolitis in childhood – may leave a lifelong one-sided hyperlucent lung (Swyer-James–MacLeod syndrome) reflecting severe air-trapping from BO. gexinonline.com
Cryptogenic (unknown cause) – even after careful workup, some cases lack an identified trigger, yet pathology and physiology match BO. PMC
Symptoms
Shortness of breath on exertion – the main complaint; narrowed small airways trap air, so exercise feels “air-starved.” NCBI
Persistent dry cough – airway scarring and irritation cause a non-productive cough that lingers for months. NCBI
Wheezing – high-pitched breathing sound from narrowed airways; often does not fully respond to typical asthma inhalers. NCBI
Exercise intolerance / easy fatigue – reduced airflow and gas exchange limit activity; people tire quickly. NCBI
Chest tightness – a sense of restricted breathing due to fixed airway narrowing. NCBI
Prolonged exhalation – patients breathe out for longer because air gets trapped behind tight bronchioles. (Obstructive physiology.) NCBI
Hypoxemia (low oxygen), especially with exertion – uneven ventilation causes oxygen to fall during activity. Lippincott Journals
Cyanosis (in advanced disease) – bluish lips or fingers can appear when oxygen is low for long periods. (Advanced obstructive disease principle.) NCBI
Frequent “bronchitis” episodes – minor infections worsen baseline symptoms because diseased small airways clear mucus poorly. (Clinical reviews.) NCBI
Morning or nighttime cough – airflow variability and airway irritability can make cough worse at those times. NCBI
Noisy breathing on exertion – airflow turbulence in narrowed bronchioles creates audible sounds during heavy breathing. NCBI
Reduced ability to climb stairs or walk briskly – simple daily tasks become hard due to limited ventilatory reserve. Lippincott Journals
In transplant patients: gradual, persistent decline in FEV₁ – often the earliest measurable change, even before severe symptoms. publications.ersnet.org
Anxiety related to breathlessness – chronic dyspnea often leads to fear and activity avoidance, which worsens deconditioning. (Common in chronic obstructive lung disease.) NCBI
Late complications: respiratory failure/cor pulmonale – long-standing hypoxemia and lung damage can strain the right heart. (Advanced obstructive lung disease principle.) NCBI
Diagnostic tests
A) Physical examination
Observing breathing pattern – doctors look for rapid breathing and use of accessory muscles. This suggests increased work of breathing from obstructed small airways. NCBI
Auscultation (listening with a stethoscope) – wheezes and prolonged expiration are common; sometimes breath sounds are uneven from region to region because some lung areas trap more air. NCBI
Percussion for hyperresonance – trapped air can make parts of the chest sound “too hollow,” hinting at hyperinflation. (Obstructive physiology.) NCBI
Pulse check after exertion – a fast heart rate with minimal activity can reflect poor ventilatory reserve and hypoxemia. Lippincott Journals
Clubbing/cyanosis check – in advanced disease, fingers may look clubbed or bluish from long-term low oxygen (not unique to BO, but supportive). NCBI
B) Manual/functional tests
Spirometry (FEV₁, FVC, FEV₁/FVC) – key test. BO shows obstruction (low FEV₁ and low FEV₁/FVC) with poor bronchodilator reversibility. This pattern helps separate BO from purely reversible asthma. NCBI
Full pulmonary function testing (lung volumes, DLCO) – air-trapping/hyperinflation can raise RV and sometimes TLC; DLCO may be reduced. NCBI
Post-transplant BOS tracking by spirometry – in lung-transplant patients, a sustained FEV₁ drop (often ≥20% from best baseline) after excluding other causes supports BOS and guides stage. publications.ersnet.org+1
Six-minute walk test – simple walk with oxygen checks. In BO, oxygen may fall with exercise (desaturation) and walking distance may be reduced. Lippincott Journals
Bronchodilator response test – helps show the obstruction is fixed (little improvement after inhaled bronchodilator), which fits BO more than asthma. NCBI
C) Laboratory & pathological tests
Autoimmune panels (e.g., RF, anti-CCP, ANA, ENA) – when BO is suspected with joint dryness, swelling, or rash, these blood tests can uncover RA/Sjögren/Lupus links. Diagnosis of cause guides treatment and exposure control. atsjournals.org
Infectious workup (viral/bacterial tests where indicated) – in post-infectious cases, historical records + targeted tests help support a prior adenovirus/RSV/Mycoplasma trigger. Karger Publishers
Biomarkers to exclude mimics – routine labs (CBC, IgE, precipitins) may point to hypersensitivity pneumonitis or other diseases that can look similar but need different management. (Review-level guidance.) pneumon.org
Transbronchial biopsies – may help in transplant follow-up, but small samples often miss the diagnostic airway rings; negative biopsy does not exclude BO. (Pathology perspective.) atsjournals.org
Surgical lung biopsy (VATS) – gold-standard when diagnosis remains unclear and risks are acceptable. Shows concentric fibrosis around membranous bronchioles with airway luminal obliteration. journalpulmonology.org
D) Electro-diagnostic / physiologic monitoring
Pulse oximetry (rest and exertion) – noninvasive, continuous oxygen reading; BO often shows exercise desaturation due to uneven ventilation. Lippincott Journals
Arterial blood gases (ABG) – measures oxygen and carbon dioxide directly. In more advanced cases, hypoxemia (low PaO₂) and sometimes CO₂ retention are seen. (Obstructive disease principles.) Lippincott Journals
ECG/echocardiography when cor pulmonale is suspected – long-standing lung disease can strain the right heart; cardiac testing helps assess complications and exclude cardiac dyspnea. (Chronic lung disease care standard.) NCBI
E) Imaging tests
High-resolution CT (HRCT) of the chest – hallmark patterns are air-trapping and mosaic attenuation, often best seen on expiratory CT; sometimes bronchiectasis and bronchial wall thickening are present. radiopaedia.org+2ajronline.org+2
Expiratory HRCT protocol – obtaining images while the patient breathes out accentuates regional air-trapping, improving detection of small-airway disease. radiopaedia.org
Chest radiograph (X-ray) – may be normal or show hyperinflation; an abnormal X-ray does not rule in or out BO, so CT is preferred. (Radiology references.) radiopaedia.org
Ventilation–perfusion (V/Q) scans (selected cases) – can reveal mismatched, patchy ventilation where air-trapping alters airflow distribution. (Imaging of small-airways disease.) PubMed
Swyer-James–MacLeod evaluation – if unilateral hyperlucency is seen (often post-infectious), further imaging confirms regional air-trapping and reduced vascularity. gexinonline.com
Serial imaging for progression – repeat HRCTs in complex or transplant cases can document air-trapping spread and structural changes over time. (Transplant/CLAD follow-up.) PMC
Diffusing-capacity mapping (via PFT lab, not imaging) – while not an image, DLCO often decreases and helps quantify gas-exchange impairment alongside imaging findings. NCBI
Putting it together: In a non-transplant patient, the combination of classic HRCT findings, fixed obstructive spirometry, a compatible history (e.g., a severe infection or meaningful exposure), and, when needed, surgical lung biopsy usually establishes the diagnosis. In transplant patients, ISHLT BOS criteria use sustained FEV₁ decline after ruling out other causes (like infection or anastomotic issues) to define and stage BOS/CLAD. publications.ersnet.org+1
Non-pharmacological (non-drug) treatments
Pulmonary rehabilitation – supervised exercise + education improves breathlessness, walking distance, quality of life in chronic lung disease; adapt programs for BO. atsjournals.org+1
Long-term oxygen therapy (LTOT) for documented severe hypoxemia (resting or exertional), following guideline criteria; improves survival/quality of life in hypoxemic chronic lung disease. atsjournals.org+1
Vaccination (influenza, pneumococcal; plus routine immunizations) to reduce infection-triggered decline. PubMed
Trigger avoidance – strict avoidance of industrial/household fumes, smoke, aerosols, dusts; occupational health interventions where relevant (respirators, ventilation). Cleveland Clinic
Airway clearance (active cycle of breathing, devices) for selected patients with mucus burden. NCBI
Breathing techniques (pursed-lip breathing), pacing, and energy conservation strategies to reduce dynamic air-trapping during activity. atsjournals.org
Nutrition optimization – adequate calories, protein; manage under- or overweight to ease ventilatory load. atsjournals.org
Psychological support – anxiety management improves perceived dyspnea and participation in rehab. American Thoracic Society
Smoking/vaping cessation – essential; vaping flavoring agents (e.g., diacetyl) have been implicated in airway injury. Cleveland Clinic
Environmental control at home – reduce irritants, improve airflow, avoid high-fume cleaners/sprays. Cleveland Clinic
Infection prevention practices – hand hygiene, early reporting of respiratory infections to clinicians. PubMed
Pulmonary rehab education modules – inhaler technique, action plans, recognizing exacerbations. atsjournals.org
Sleep optimization – treat co-existing sleep apnea where present to reduce cardiorespiratory strain. atsjournals.org
Workplace evaluation – occupational medicine assessment for exposure removal or re-assignment. Cleveland Clinic
Home safety for oxygen – education on concentrators/cylinders; fire and trip hazards. PubMed
Early pulmonary rehab after flare – speeds recovery and improves function vs usual care. PMC
Assistive devices (rolling walker with seat, shower chair) to reduce breathlessness during tasks. atsjournals.org
Heat/humidity control – extreme heat or cold can worsen symptoms; plan activities in best conditions. atsjournals.org
Caregiver/family education – support with medications, oxygen, emergency plans. atsjournals.org
Advance care planning in advanced disease to align care with goals and preferences. NCBI
Drug treatments
Important: No drug is FDA-approved specifically for bronchiolitis obliterans. Many medicines below are used off-label to manage inflammation, airflow obstruction, or transplant-related immune pathways. FDA labels are cited for their approved indications, dosing, and safety, not for BO approval.
Azithromycin (macrolide) – In BOS after lung transplant, randomized trials and series show improvements in FEV₁ and reduced inflammation for some patients; typical regimens are low-dose, long-term (off-label in BO). Safety (QT risk, GI upset) and general indications appear in the FDA label. FDA Access Data+3thorax.bmj.com+3PubMed+3
Inhaled corticosteroid/LABA combos (e.g., budesonide/formoterol – Symbicort; fluticasone/salmeterol – Advair). They can reduce symptoms and exacerbations in obstructive lung disease; used empirically in BO to target airway inflammation/bronchospasm (off-label). Dosing and boxed warnings are detailed in FDA labels. FDA Access Data+2FDA Access Data+2
Short-acting bronchodilators (albuterol) and anticholinergics (ipratropium) for symptomatic relief of wheeze/airflow obstruction, though response may be limited. (FDA labels support indications/safety for obstructive disease.) FDA Access Data
Long-acting muscarinic antagonist (LAMA: tiotropium/Spiriva) may improve symptoms/exacerbations in fixed obstruction (off-label in BO). FDA labeling details COPD indication and dosing. FDA Access Data
Systemic corticosteroids (e.g., prednisone) – sometimes used for inflammatory flares; long-term high doses are not recommended in BOS guidelines because harm outweighs benefit. (Use, taper, and adverse effects per general corticosteroid guidance/FDA labeling for individual products.) publications.ersnet.org
Calcineurin inhibitors (tacrolimus / Prograf) – cornerstone of transplant immunosuppression; regimens are optimized in BOS settings (off-label for BOS treatment escalation). FDA labels cover transplant prophylaxis dosing and safety. FDA Access Data
Antimetabolite immunosuppressant (mycophenolate mofetil / CellCept) – used with calcineurin inhibitors in transplant recipients; adjustments are common when BOS evolves (off-label for BOS per se). FDA label details dosing and significant infection risks. FDA Access Data
Azathioprine – older antimetabolite sometimes used in specific contexts; careful monitoring for cytopenias/infections (label for transplant/autoimmune diseases, off-label for BOS). PubMed
Montelukast (Singulair) – leukotriene-receptor antagonist occasionally tried to reduce airway inflammation/bronchospasm (off-label in BO). FDA label provides dosing and neuropsychiatric warnings. FDA Access Data+1
Inhaled budesonide (as standalone) – sometimes used where LABA isn’t tolerated; evidence in BO is limited (off-label). FDA labeling exists for asthma/COPD products. FDA Access Data
Extracorporeal photopheresis (ECP) – a procedural immunomodulatory therapy rather than a drug, but often co-managed with medications; observational data show stabilization/improvement in some BOS patients, and CMS covers it under evidence development criteria post-lung transplant. PubMed+1
Proton-pump inhibitors in reflux/aspiration management after transplant (supportive, not disease-modifying). PubMed
Antivirals/antibiotics during documented infections (to avoid further airway injury). Use per pathogens and labels. PubMed
Antifungals (in transplant settings) when indicated by culture/surveillance. PubMed
Trimethoprim-sulfamethoxazole prophylaxis in some transplant regimens (Pneumocystis prevention). PubMed
Statins (investigational/adjunctive immune modulation in some transplant centers; evidence inconsistent). PubMed
Sirolimus (mTOR inhibitor) – occasionally used when calcineurin toxicity limits therapy; transplant-label safety/dosing apply; impact on BOS varies and is individualized. PubMed
Inhaled bronchodilator nebulizers for symptom relief before activity (albuterol ± ipratropium). Labeling supports dosing and safety. FDA Access Data
Macrolide alternatives (clarithromycin) when azithromycin is not tolerated; less evidence than azithromycin in BOS. (Labeling supports antimicrobial use, not BO.) PubMed
Vaccinations are biologics, not drugs for treatment, but are critical to prevent infection-related decline and are routinely recommended in transplant/BO care pathways. PubMed
Dietary molecular supplements
No supplement is proven to treat or reverse bronchiolitis obliterans. If used, they should be adjuncts for overall lung and immune health, with clinician oversight (especially in transplant patients where drug–supplement interactions are important).
Omega-3 fatty acids – anti-inflammatory effects; may support cardiovascular health and systemic inflammation control; watch bleeding risk with anticoagulants. atsjournals.org
Vitamin D – supports bone/immune health; deficiency is common with steroids and in chronic disease; monitor levels to avoid toxicity. atsjournals.org
Calcium + vitamin D – bone protection if corticosteroids are used; dosing individualized. atsjournals.org
N-acetylcysteine (NAC) – antioxidant/mucolytic; mixed evidence; check interactions and renal/liver status. atsjournals.org
Magnesium – helpful if beta-agonists lower serum magnesium; avoid excess. atsjournals.org
Protein supplementation – supports respiratory muscles in undernutrition; dietitian-guided. atsjournals.org
Multivitamin/mineral – general support in poor intake; avoid high-dose fat-soluble vitamins without monitoring. atsjournals.org
Probiotics – gut side-effect support during antibiotics; evidence disease-specific to BO is absent. atsjournals.org
Coenzyme Q10 – sometimes used for statin myalgias if statin used; data limited. atsjournals.org
Electrolyte solutions – for hydration in rehab/exercise; watch sodium if hypertensive. atsjournals.org
Drugs for immunity booster / regenerative / stem-cell
Important safety note: There is no proven “immune booster” or stem-cell drug that reverses bronchiolitis obliterans. In transplant patients, unsupervised “immune boosters” can increase rejection or interact with calcineurin inhibitors. The options below are immunomodulators used in transplant care, not generic “boosters,” and any cell-based therapy should be limited to clinical trials.
Tacrolimus (calcineurin inhibitor) – prevents allograft rejection; dosing by trough levels; risks include infection, nephrotoxicity, neurotoxicity. (FDA-approved for transplant prophylaxis; not BO-specific.) FDA Access Data
Mycophenolate mofetil – inhibits lymphocyte proliferation; reduces rejection risk; monitor for cytopenias/infections/teratogenicity. (Transplant label.) FDA Access Data
Sirolimus (mTOR inhibitor) – alternate immunosuppression; monitor for mouth ulcers, dyslipidemia, delayed wound healing. (Transplant use; BOS role individualized). PubMed
Extracorporeal photopheresis (procedure) – immunomodulatory effect with some BOS stabilization in series; generally for post-transplant BOS within programs meeting coverage criteria. PubMed+1
IVIG in selected immune-mediated or infection-prone scenarios post-transplant (center-specific); evidence variable. PubMed
Stem-cell therapies – experimental only for BO; should be given only in regulated clinical trials; no approved product for BO reversal. NCBI
Surgeries/procedures
Lung transplantation – for refractory disease with severe limitation despite maximal therapy; contemporary series show reasonable outcomes in carefully selected BOS patients. PubMed+2jhltonline.org+2
Tracheostomy – rarely for BO alone; may be considered for airway clearance/ventilation in very advanced, complicated cases. NCBI
Bronchoscopic evaluation – procedural assessment to exclude treatable infection or complications; not curative. PubMed
Anti-reflux surgery (selected post-transplant patients with severe reflux/aspiration contributing to allograft injury; center-specific). PubMed
Photopheresis access procedures – vascular access for ongoing ECP sessions in BOS after lung transplant (when indicated). cms.gov
Preventions (practical)
Avoid industrial/household chemical fumes; use protective equipment and ventilation at work. Cleveland Clinic
No smoking or vaping (avoid diacetyl-containing flavorings). Cleveland Clinic
Vaccinations up to date (influenza, pneumococcal, and others per national schedule). PubMed
Early treatment of chest infections to limit further airway injury. NCBI
Hand hygiene and sick-contact precautions during viral seasons. PubMed
Reflux control (diet, timing, head-of-bed elevation; medical/surgical per specialist in post-transplant BOS). PubMed
Pulmonary rehab and fitness to maintain lung function and muscle strength. atsjournals.org
Air quality awareness (heat/cold/wildfire smoke days—stay indoors with filtration if advised). atsjournals.org
Medication adherence (especially immunosuppressants after transplant) with therapeutic drug monitoring. FDA Access Data
Regular follow-up with pulmonary/transplant teams for early detection of decline. PubMed
When to see a doctor (or seek urgent care)
Rapidly worsening shortness of breath, new oxygen needs, or resting breathlessness.
High fever, chest pain, or coughing colored sputum suggesting infection.
Blue lips/fingertips, confusion, or fainting (possible hypoxemia).
After lung or stem-cell transplant, any drop in home spirometry or persistent cough/wheeze.
New exposure to strong fumes with breathing difficulties afterward. NCBI+1
Diet: things to eat and avoid (supportive)
What to eat
Lean protein (fish, poultry, legumes) to maintain respiratory muscles.
Fruits/vegetables for micronutrients and fiber.
Whole grains for steady energy during rehab.
Healthy fats (olive oil, nuts) to meet calories without excess bloating.
Adequate fluids to thin mucus unless restricted. atsjournals.org
What to avoid/limit
Ultra-processed, high-salt foods if fluid retention or steroids raise BP.
Large meals before activity (worsens breathlessness).
Alcohol excess (drug interactions; transplant patients often must avoid).
Smoke/fume-exposed foods if they trigger cough.
Unpasteurized foods or raw meats in immunosuppressed patients (infection risk). FDA Access Data
FAQs
1) Is bronchiolitis fibrosa obliterans reversible?
Not usually. The small airways become scarred and narrowed. Treatments focus on slowing decline, reducing symptoms, and preventing complications. Lung transplant may be an option if disease is advanced. NCBI+1
2) How is it different from asthma or COPD?
Asthma is usually reversible with bronchodilators; BO typically shows fixed obstruction with poor reversibility. COPD affects larger and smaller airways and alveoli; BO is primarily a small-airway scarring disorder. Wikipedia
3) What does the CT scan show?
Mosaic attenuation and air-trapping, especially on expiratory images, are classic. NCBI
4) Do inhalers help?
They may relieve symptoms, but they often don’t change the disease course. Some patients feel better with LAMA/LABA/ICS combos; your doctor will individualize therapy. FDA Access Data+1
5) Does azithromycin really work?
In BOS after lung transplant, randomized data show FEV₁ improvement for a subset. It’s off-label and requires screening for QT risks and drug interactions. thorax.bmj.com
6) Is long-term oxygen therapy beneficial?
Yes—if you meet criteria for severe hypoxemia, guidelines recommend LTOT for ≥15 hours/day; it improves outcomes in chronic hypoxemia. atsjournals.org
7) Can pulmonary rehab help?
Yes. It reduces breathlessness and improves exercise capacity and quality of life in chronic lung disease; it’s a cornerstone of supportive care. atsjournals.org
8) Are “immune boosters” safe after transplant?
Generally no without specialist approval. Many supplements interact with transplant drugs and can raise rejection or infection risks. FDA Access Data
9) Is extracorporeal photopheresis an option?
It’s used in some centers for post-transplant BOS with observational evidence of stabilization; coverage may require registry participation. PubMed+1
10) What if my disease was caused by workplace exposure?
An occupational medicine evaluation is essential to remove exposure and support accommodations. Cleveland Clinic
11) Do I need a biopsy?
Often no. Because lesions are patchy and biopsy is invasive, diagnosis usually relies on clinical picture + PFT + HRCT and excluding mimics. NCBI
12) Can diet cure it?
No diet cures BO, but good nutrition supports muscle strength, energy for rehab, and medication tolerance. atsjournals.org
13) What about montelukast or inhaled steroids?
They can be tried for symptoms in selected patients, but evidence is limited and use is off-label. Monitor benefit closely. (See FDA labels for dosing/safety.) FDA Access Data+1
14) When is transplant considered?
When symptoms, oxygen needs, and lung function decline despite optimal therapy and you otherwise meet transplant criteria. PubMed+1
15) What is BOS?
Bronchiolitis obliterans syndrome—the clinical manifestation of chronic lung allograft dysfunction after lung transplantation characterized by persistent airflow limitation. It’s guided by international ISHLT/ATS/ERS criteria. PubMed
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: November 03, 2025.
